Erenumab for headaches in idiopathic intracranial hypertension: A prospective open‐label evaluation

Abstract

This study provides evidence for the effectiveness of erenumab to treat headaches in IIH patients with resolution of papilledema. It provides mechanistic insights suggesting that calcitonin gene-related peptide is likely a modulator driving headache and a useful therapeutic target.